The FDA granted an expanded approval to Opdivo (nivolumab) as a single agent and in combination with Yervoy (ipilimumab) on January 23 for the treatment of patients with melanoma who harbor BRAF V600 mutations. As a result of the expansion, Opdivo is now available as a frontline treatment for all patients with advanced melanoma, regardless of BRAF status.
Publications
FDA grants orphan drug designation to IMCgp100 for uveal melanoma
The FDA granted orphan drug designation to IMCgp100 for the treatment of uveal melanoma.
IMCgp100 (Immunocore) is part of a class of bispecific biologic reagents known as ImmTACs, or immune-mobilizing monoclonal T-cell receptors against cancer.
Improved Progression-Free, Overall Survival Achieved With Dabrafenib, Trametinib Combo in Melanoma
Dabrafenib plus trametinib achieves good overall and progression-free survival in BRAF inhibitor-naïve patients with BRAF V600 mutation-positive metastatic melanoma, a study published online ahead of print in the Journal of Clinical Oncology has shown.1
ASCO: Immunotherapy is ‘Cancer Advance of the Year’
ASCO has named progress in immunotherapy for melanoma and other malignancies as the top cancer advance of the year, according to “Clinical Cancer Advances 2016: ASCO’s Annual Report on Progress Against Cancer.”